The third-generation EGFR-targeting anti-cancer drug Tagrisso (Osimertinib) has left a unique record in non-small cell lung cancer. Significant improvement was achieved in adjuvant therapy after surgery, and it was also proven that survival time could be extended. This is an area that previous TKI drugs have failed to overcome. Tagrisso has already demonstrated that it can reduce the risk of recurrence or death by about 80% through the phase 3 clinical trial of ADUARA three years ago. Since then, people's attention has been focused on overall survival. I wondered how much longer actual patients could live if Tagrisso was used early.

The results were revealed at ASCO 2023 held this year. As a result of anal